Conflicts of Interests Statement 2012-2014

The COPD Guidelines Evaluation Committee is responsible for updating the COPD-X Guidelines. All below-named members of the COPD Guidelines Evaluation Committee are required to lodge declarations of potential conflicts of interest with Lung Foundation Australia on an annual basis. Such disclosures include the receipt of unrestricted educational grants, sponsorship, consultancy or other affiliations with the pharmaceutical, medical equipment or diagnostic industries.

Committee Member

Conflict of interest declaration

Professor Michael Abramson MB BS BMedSc(Hons), PhD, FRACP, FAFPHM – Deputy Head, School of Public Health and Preventive Medicine, Monash University, Melbourne VIC

I hold investigator initiated research grants from Pfizer (2012 – 2014) and Boehringer Ingelheim. (2014)

I received support to attend the ERS Congress from Boehringer Ingelheim. (2013)  I attended the Respiratory Symposium funded by Novartis. (2014)  I have been paid honoraria by AstraZeneca (2013) and Novartis. These do not constitute substantial sources of income. (2014)

Professor Alan Joseph Crockett PSM, MPH, PhD, FANZSRS– Professor of Clinical Respiratory Physiology, Division of Health Sciences, University of South Australia;  Emeritus Fellow, Discipline of General Practice, School of Population Health and Clinical Practice, University of Adelaide, Adelaide SA

No competing interests to declare


Dr Eli Dabscheck MBBS, FRACP – Staff Specialist, Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne VIC

Attended Airways conference funded by Novartis. (2014)

Professor Peter A Frith MBBS, FRACP, FThorSoc– Professor in Respiratory Medicine, Flinders University; Thoracic Physician, Flinders Medical Centre and Repatriation General Hospital, Daw Park SA

I have received small honorarium payments for work associated with COPD Advisory Boards and ad hoc expert advice (covered by confidentiality agreements), GP education, scientific organising committees and speaker engagements from AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, MundiPharma, Novartis, Takeda-Nycomed. (2014)

I have received travel support for attending national and international scientific meetings from Novartis, Boehringer, and GlaxoSmithKline.

Non-financial potential conflicts of interest exist from work performed as Board member of the Global Initiative for Obstructive Lung Disease (GOLD), Global Alliance for Respiratory Diseases (GARD) and National Asthma Council Australia. (NACA). (2014)

The clinical trials unit of which I am Director undertakes contracted research for many pharmaceutical companies, which provides access to early information about multiple new drugs and devices (covered by confidentiality agreements). (2014)

Small honoraria for Advisory Boards of AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Medimark and Remedy Healthcare. (2013)

Small honorarium for Advisory Boards of AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Nycomed-Takeda. (2012)

Dr Johnson George, Senior Lecturer, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne VIC

Recipient of an Investigator-initiated research grant from Pfizer. However, Pfizer had no involvement in the design of this study, its evaluation or outcomes. (2014)

CIA of an NHMRC Partnership grant focusing on smoking cessation and management of COPD in primary care – Boehringer Ingelheim, Inner Eastern Melbourne Medicare Local and Lung Foundation Australia are partner organisations on this grant. BI was not involved in the study design and will not be involved in data analysis, interpretation of findings or its reporting. A research agreement between Monash University and BI will be signed before initiation of the project. (2014)

Chief Investigator of an Investigator-initiated Research Grant from Pfizer ($175,000) investigating pharmacist-initiated smoking cessation support for in-patients. (2013)

Chief Investigator of Australian Respiratory Council (ARC) Linkage Grant application under review with Boehringer Ingelheim Pty Ltd (BI), Lung Foundation Australia and Inner Eastern Melbourne Medicare Local as Industry partners. (2013)

Chief Investigator of a Monash University Research Impact Fund (MRIF) supported project focusing on remote monitoring of asthma in pregnant women.  The project has received some in-kind contributions (valued at approximately $1000) from Vitalograph Inc. (2013)

Professor Nicholas Glasgow BHB, MBChB, GradDipFamMed, GradCertHigherEd, MD, FRNZGP, FRACGP, FAChPM Dean, Medicine and Health Sciences, College of Medicine, Biology and Environment, The Australian National University, Canberra, ACT

Member of National Lead Clinicians Group appointed by the Australian Government Minister for Health. (2012)

Associate Professor Sue Jenkins PhD, GradDipPhys – School of Physiotherapy, Curtin University, Physiotherapy Department, Sir Charles Gairdner Hospital, Perth, WA

Member of Organising Committee and Session Chair of Airways education meeting funded by Boehringer Ingelheim. (2014)

Member of Menarini COPD Advisory Board (attended one Board meeting). (2014)

Received honorarium from Boehringer for contribution to a scientific meeting. (2012)

Professor Christine F McDonald MB BS (Hons), PhD, FRACP – Director, Department of Respiratory and Sleep Medicine, Austin Hospital, Heidelberg, VIC

Our Department participates in sponsored clinical trials with a range of companies, including Takeda, Boehringer Ingelheim, Novartis, Pearl, GSK, Apnex (2012-2014).

I am involved in investigator initiated studies funded (2012-2014) through NHMRC, Eirene Lucas Foundation, Institute for Breathing and Sleep, American Thoracic Society Pulmonary Fibrosis Foundation, Austin Medical Research Foundation, Institute for a Broadband Enabled Society.

Membership advisory boards for Pfizer, Boehringer Ingelheim, Novartis.  Honoraria received for speaking at educational meetings sponsored by Novartis and Boehringer Ingelheim. Speaker at GSK symposium (no honorarium).

Associate Professor David Kenneth McKenzie PhD, FRACP – Head of Department, Respiratory and Sleep Medicine, Prince of Wales Hospital, Randwick NSW

I am involved in clinical trials which are conducted by pharmaceutical companies for which my Department is paid on a fee for service basis. In my private practice I provide medico legal reports to law firms and other parties on various matters on a fee for service basis (2014)

Dr Richard Wood-Baker DM, BS, MRC(I), MRCP(UK), FRCP, MEd – Director of Cardiorespiratory Medicine, Royal Hobart Hospital;  Honorary Fellow, Menzies Research Institute, Hobart TAS

No competing conflicts to declare.

Associate Professor Ian Yang MBBS(Hons), PhD, FRACP, Grad Dip Clin Epid, Thoracic Physician, The Prince Charles Hospital; School of Medicine, The University of Queensland, Brisbane QLD

Unrestricted grant from Novartis to establish a severe asthma service, which was paid to The Prince Charles Hospital Foundation (2013) 

No advisory boards or consultancies to declare.

Professor Nick Zwar, MBBS, MPH, PhD, FRACGP, Professor of General Practice, School Public Health & Community Medicine, Faculty of Medicine, University of New South Wales, NSW

No competing interests to declare

NOTE: Conflicts of Interest correct at January 2014